

LIFE SAVING DRUGS PROGRAM EXPERT PANEL

19th MEETING: 13 December 2024 AGENDA

1. Standing business

- 1.1. Welcome, apologies and Conflicts of Interest
- 1.2. Update on actions from previous meetings
- 1.3. Correspondence
- 1.4. Report from the secretariat

2. 24 month review of existing LSDP medicines

- 2.1. Avalglucosidase alfa (Nexviazyme®) – for the treatment of Pompe disease

3. Applications for new LSDP medicines

- 3.1. Olipudase alfa (Xenpozyme®) – for the treatment of acid sphingomyelinase deficiency (ASMD) types A/B and B

4. Other business

- 4.1. Enhance HTA report